Were (or their designated health care proxy holders) consented prior to

September 25, 2017

Were (or their designated health care proxy holders) consented prior to the screening.Study Population and Data CollectionAdult patients with ACHBLF who were willing to participate and consented to the study were screened for the following eligibility criteria: (1) age of 18?0 years; (2) meeting the diagnostic criteria of ACHBLF which included jaundice (serum bilirubin >5 mg/dl [85 umol/l]) and JSH-23 custom synthesis coagulopathy (INR = 1.5 or pro> = thrombin activity,40 ), ascites and/or encephalopathy as determined by physical examination within 4 weeks of the disease onset, and previously diagnosed chronic hepatitis B. (3) exacerbation of CHB for the first time. Key exclusion criteria were the followings: the time point of acute onset of ACHBLF was more than 14 days prior to the enrollment date; clinical evidence of cirrhosis or documented stage IV fibrosis on liver biopsy (if available); co-infection with hepatitis A, C, D, E or HIV virus; pregnant woman; diagnosis of other liver diseases including autoimmune hepatitis and Wilson disease, or evidence of hepatic tumor; history of renal, cardiovascular, pulmonary, endocrine or neurological diseases; history of antiviral therapy prior to the onset of ACHBLF, history of drug abuse including alcohol abuse; treatment with immune modulator, antibiotic treatment, or Chinese herbal medicine within six months prior to the screening. Patients enrolled were followed every week by research team until week 12. As per good clinical practice standard, IPI549 site further interventions for ACHBLF in addition to supportive care were allowed and decided by clinical team members who were blind to the protocol, which included referral for liver transplant, providing antiviral treatment or using antibiotic when sepsis developed. However, only patients who were on supportive care without interventions during the study period were analyzed to delineate the relationship between LPS levels and disease severity in ACHBLF. Total bilirubin (TBil) levels were used as the marker for disease phases in ACHBLF. According to the dynamic change of TBil, the phases of ACHBLF in this study were defined as the following: 1) progression phase, which was from the onset of ACHBLF (at the time of diagnosis of ACHBLF) to the point of peak level of TBil; 2) peak phase, which was the period when TBil level plateaued after reaching the peak; and 3) remission phase, which was from the point of decrease in TBil after plateauing toDynamic Changes of LPS in ACLF with HBVthe return of TBil level to the baseline. Although clinical parameters were measured and LPS samples were obtained 1407003 weekly, only 1? samples collected during each phase of ACHBLF (selected at the mid time point of the phase) were used to determine the LPS level in the individual phase. Available serum and plasma samples were measured in our research laboratory. Patients’ HBV DNA levels, HBeAg and HBsAg status, ALT, albumin, creatinine, prothrombin time, model for end stage liver disease scores with sodium (MELD-Na) were recorded in all subjects at one week interval. Data for healthy volunteers were also prospectively collected and their blood samples were measured for LPS levels and TBil level in the same laboratory. The standard of supportive care for ACHBLF at the study center was the following: patients routinely received high calorie diet (35?0 Cal/kg/day) with reduced glutathione. Patients also received proton pump inhibitors, enteral/parenteral nutrition, and albumin transfusion if needed.Results.Were (or their designated health care proxy holders) consented prior to the screening.Study Population and Data CollectionAdult patients with ACHBLF who were willing to participate and consented to the study were screened for the following eligibility criteria: (1) age of 18?0 years; (2) meeting the diagnostic criteria of ACHBLF which included jaundice (serum bilirubin >5 mg/dl [85 umol/l]) and coagulopathy (INR = 1.5 or pro> = thrombin activity,40 ), ascites and/or encephalopathy as determined by physical examination within 4 weeks of the disease onset, and previously diagnosed chronic hepatitis B. (3) exacerbation of CHB for the first time. Key exclusion criteria were the followings: the time point of acute onset of ACHBLF was more than 14 days prior to the enrollment date; clinical evidence of cirrhosis or documented stage IV fibrosis on liver biopsy (if available); co-infection with hepatitis A, C, D, E or HIV virus; pregnant woman; diagnosis of other liver diseases including autoimmune hepatitis and Wilson disease, or evidence of hepatic tumor; history of renal, cardiovascular, pulmonary, endocrine or neurological diseases; history of antiviral therapy prior to the onset of ACHBLF, history of drug abuse including alcohol abuse; treatment with immune modulator, antibiotic treatment, or Chinese herbal medicine within six months prior to the screening. Patients enrolled were followed every week by research team until week 12. As per good clinical practice standard, further interventions for ACHBLF in addition to supportive care were allowed and decided by clinical team members who were blind to the protocol, which included referral for liver transplant, providing antiviral treatment or using antibiotic when sepsis developed. However, only patients who were on supportive care without interventions during the study period were analyzed to delineate the relationship between LPS levels and disease severity in ACHBLF. Total bilirubin (TBil) levels were used as the marker for disease phases in ACHBLF. According to the dynamic change of TBil, the phases of ACHBLF in this study were defined as the following: 1) progression phase, which was from the onset of ACHBLF (at the time of diagnosis of ACHBLF) to the point of peak level of TBil; 2) peak phase, which was the period when TBil level plateaued after reaching the peak; and 3) remission phase, which was from the point of decrease in TBil after plateauing toDynamic Changes of LPS in ACLF with HBVthe return of TBil level to the baseline. Although clinical parameters were measured and LPS samples were obtained 1407003 weekly, only 1? samples collected during each phase of ACHBLF (selected at the mid time point of the phase) were used to determine the LPS level in the individual phase. Available serum and plasma samples were measured in our research laboratory. Patients’ HBV DNA levels, HBeAg and HBsAg status, ALT, albumin, creatinine, prothrombin time, model for end stage liver disease scores with sodium (MELD-Na) were recorded in all subjects at one week interval. Data for healthy volunteers were also prospectively collected and their blood samples were measured for LPS levels and TBil level in the same laboratory. The standard of supportive care for ACHBLF at the study center was the following: patients routinely received high calorie diet (35?0 Cal/kg/day) with reduced glutathione. Patients also received proton pump inhibitors, enteral/parenteral nutrition, and albumin transfusion if needed.Results.